Classification of Asthma Severity in a 3-Year-Old Child: A Case Study

QUESTION

BG, is a 3 year old male who has recently experienced an anaphylactic reaction to bees. After being stung BG experienced redness, angioedema, acute laryngitis, coughing, vomiting, and wheezing. At the hospital he was prescribed an epinephrine auto injector .15 mg PRN upon exposure to allergen.

BG also has moderate intermittent asthma exacerbated by allergies and illness, for which he has been prescribed montelukast 4 mg PO QHS. Additionally BG has been prescribed albuterol MDI 90 mcg per actuation; 2 inhalations administered as needed for shortness of breath, wheezing, bronchospasm, or chest tightness.

Identify BG’s for Classification of Asthma Severity level.
Does he mild, moderate, severe and persistent or intermittent?

ANSWER

Classification of Asthma Severity in a 3-Year-Old Child: A Case Study

Introduction

Asthma is a chronic respiratory condition characterized by airway inflammation and bronchial hyperresponsiveness. It can vary in severity and frequency of symptoms, requiring appropriate classification to guide treatment decisions. This essay aims to identify the classification of asthma severity in BG, a 3-year-old male, based on his clinical presentation and prescribed medications.

Classification of Asthma Severity

Determining the severity level of asthma in children involves assessing the frequency and intensity of symptoms, as well as the need for medication to maintain control. The Global Initiative for Asthma (GINA) guidelines provide a widely accepted framework for classifying asthma severity in both adults and children.

Based on BG’s clinical presentation and prescribed medications, his asthma can be classified as moderate intermittent.

Explanation

Mild Intermittent Asthma: This classification is characterized by symptoms occurring ≤2 days per week, nighttime awakenings ≤2 times per month, and the absence of any interference with normal activities. Short-acting beta-agonists (SABA) such as albuterol are used for symptom relief as needed.

Moderate Intermittent Asthma: BG’s asthma aligns with this classification as he experiences symptoms more frequently than mild intermittent asthma. Moderate intermittent asthma is defined by symptoms occurring >2 days per week but not daily, nighttime awakenings >2 times per month, and minor limitations in daily activities. SABA remains the mainstay of treatment, but additional therapy may be required to achieve control. In BG’s case, montelukast, a leukotriene receptor antagonist, is prescribed to manage his asthma and provide additional anti-inflammatory effects.

It is important to note that BG’s recent anaphylactic reaction to bees does not affect the classification of his asthma severity but underscores the need for prompt treatment with epinephrine autoinjector in the event of future allergen exposure.

Conclusion

Based on the provided information, BG’s asthma can be classified as moderate intermittent. This classification reflects his symptom frequency, the need for daily controller medication (montelukast), and the use of short-acting beta-agonist (albuterol) for symptom relief. Asthma classification serves as a guide for treatment decisions and helps healthcare professionals develop an individualized management plan to optimize control and improve the quality of life for children like BG.